Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-Vaxx plus chemotherapy in advanced gastric cancer
NCT02795988Phase 2Completed
- Sponsor
- Imugene
- Start
- Aug 2017
- Primary completion
- Mar 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics, Adoptive Cell Transfer
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of HER-Vaxx in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Imugene. Primary endpoints: Number of Participants With Adverse Events at 7 months, Overall Survival at 30 months and 1 more. Started Aug 2017; status: completed.
02
Drugs
HER-Vaxx
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02795988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795988.